Loading…
Develops oral bradykinin receptor antagonists to treat hereditary angioedema attacks.
Develops oral bradykinin receptor antagonists to treat hereditary angioedema attacks.
Has no product on the market yet, so it earns no sales and is funded by money raised from investors. Dutch-incorporated, with research and operations in Switzerland and the Netherlands. Its drug is a pill taken at the start of an attack, so convenience is its main differentiator.
Moat: none (IP / patents). Differentiated oral mechanism vs injectable HAE standards, but still clinical-stage with no approved product.
Headquarters: Zug, Switzerland · Founded: 2018 · Employees: 129
Size Pharvaris (PHVS) is a United States Health Care company (Biotechnology) with a market value of $2.41B, the 1680th largest of 3,117 United States companies the cockpit tracks. Shares closed at $34.39 on 6 Nov 2026.
Performance Over six months the shares gained 14.3%, against -3.9% for the median peer and -1.1% for the United States market (cap-weighted) — 8th highest of 20 in its peer set.
Short interest Short interest is 3.5% of the free float (15 Oct 2026).
Next results Next results expected around 18 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$575,937 | -$472,144 | -$291,583 | -$278,442 | -$160,737 |
| EBITDA | -$212M | -$191M | -$157M | -$104M | -$91.0M |
| Net income | -$199M | -$198M | -$145M | -$109M | -$80.2M |
| Free cash flow | -$183M | -$155M | -$131M | -$101M | -$70.7M |
| Capital expenditure | $119,831 | $185,785 | $582,043 | $97,283 | $130,632 |
| Total debt | $770,273 | $912,310 | $892,052 | $263,906 | $466,198 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Pharvaris PHVS | $2.41B | +14% | n/a | n/a | n/a | n/a |
| BioCryst Pharmaceuticals BCRX | $1.97B | -11% | +60% | 42% | 2.5× | -10.6% |
| Ionis Pharmaceuticals IONS | $6.55B | -48% | -7% | -68% | 7.7× | n/a |
| Takeda Pharmaceutical 4502.T | $66.4B | +24% | +6% | 18% | 3.1× | 3.0% |
| Pharming PHARM.AS | $874M | -2% | +2% | 9% | 2.1× | 2.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PHVS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +10.5% | -0.8% | 7th highest of 21 |
| 6-month return | +14.3% | -3.9% | 8th highest of 20 |
| Distance from 52-week high | -20.5% | -33.3% | 8th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Pharvaris PHVS | United States | $2.41B | +14% | n/a | n/a | n/a | n/a | n/a |
| BGI Genomics 300676.SZ | China | $2.39B | -4% | 0% | -14% | 3.7× | n/a | n/a |
| MBX Biosciences MBX | United States | $2.47B | +25% | n/a | n/a | n/a | n/a | n/a |
| Celldex Therapeutics CLDX | United States | $2.35B | -12% | -97% | -206,220% | 10,375.3× | n/a | n/a |
| Zealand Pharma A/S ZEAL.CO | Denmark | $2.32B | -32% | -49% | 51% | 0.3× | n/a | n/a |
| Palvella Therapeutics PVLA | United States | $2.53B | +45% | -100% | n/a | n/a | n/a | n/a |
| Hemab Therapeutics COAG | United States | $2.29B | +95% | n/a | n/a | n/a | n/a | n/a |
| Septerna SEPN | United States | $2.28B | +105% | +13,520% | -57% | 19.5× | 18.7% | n/a |
| Vimian VIMIAN.ST | Sweden | $2.26B | +41% | +8% | 19% | 4.9× | 12.5% | +44.5% |
| Evopoint Biosciences 688837.SS | China | $2.58B | n/a | n/a | n/a | 67.9× | n/a | n/a |
| Arcus Biosciences RCUS | United States | $2.59B | -28% | -55% | -415% | 17.1× | n/a | n/a |
| Sinocelltech 688520.SS | China | $2.25B | -23% | -40% | -75% | 15.6× | n/a | n/a |
| SKBS 302440.KS | South Korea | $2.22B | -11% | +23% | -25% | 4.5× | n/a | n/a |
| Immunome IMNM | United States | $2.21B | -17% | -100% | n/a | n/a | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.21B | +8% | +21% | 45% | 5.5× | 5.1% | +41.4% |
| Recursion Pharmaceuticals RXRX | United States | $2.19B | +6% | +56% | -725% | 25.1× | n/a | n/a |
| Xencor XNCR | United States | $2.66B | +178% | -29% | -206% | 22.6× | n/a | n/a |
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.19B | +25% | +259% | 60% | n/a | n/a | n/a |
| Hebei Changshan Biochemical Pharmaceutical 300255.SZ | China | $2.68B | -52% | 0% | -25% | 21.9× | n/a | n/a |
| Walvax Biotechnology 300142.SZ | China | $2.71B | -12% | -23% | 5% | 10.3× | 31.3% | -3.8% |
| Vera Therapeutics VERA | United States | $2.15B | -18% | n/a | n/a | n/a | n/a | n/a |